Vir Biotechnology, Inc. Basic Shares Outstanding (Weighted Average)
Vir Biotechnology, Inc. (VIR) reported Basic Shares Outstanding (Weighted Average) of 167.72 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 167.72M shares, a 21.14% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 147.36M shares, a 7.19% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 139.22M shares, a 1.76% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 138.93M shares, a 1.67% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 138.52M shares, a 1.67% increase from fiscal 2024.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 136.25M shares, a 1.58% increase from fiscal 2023.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 134.13M shares, a 1.15% increase from fiscal 2022.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 132.61M shares, a 2.10% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 167.72M shares 10-Q · filed 2026-08-05 | 157.61M shares 10-Q · filed 2026-08-05 | 151.43M shares derived: average of 3 quarters · filed 2026-08-05 | 148.31M shares derived: average of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | 147.36M shares 10-Q · filed 2026-05-07 | 143.29M shares derived: average of 2 quarters · filed 2026-05-07 | 141.84M shares derived: average of 3 quarters · filed 2026-05-07 | 140.99M shares derived: average of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | 139.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 139.07M shares derived: average of 2 quarters · filed 2026-02-23 | 138.87M shares derived: average of 3 quarters · filed 2026-08-05 | 138.52M shares 10-K · filed 2026-02-23 | |
| 2025-09-30 | 138.93M shares 10-Q · filed 2025-11-05 | 138.69M shares derived: average of 2 quarters · filed 2026-08-05 | 138.29M shares 10-Q · filed 2025-11-05 | 137.91M shares derived: average of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | 138.45M shares 10-Q · filed 2026-08-05 | 137.96M shares 10-Q · filed 2026-08-05 | 137.58M shares derived: average of 3 quarters · filed 2026-08-05 | 137.35M shares derived: average of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | 137.47M shares 10-Q · filed 2026-05-07 | 137.14M shares derived: average of 2 quarters · filed 2026-05-07 | 136.98M shares derived: average of 3 quarters · filed 2026-05-07 | 136.79M shares derived: average of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | 136.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 136.73M shares derived: average of 2 quarters · filed 2026-02-23 | 136.56M shares derived: average of 3 quarters · filed 2026-02-23 | 136.25M shares 10-K · filed 2026-02-23 | |
| 2024-09-30 | 136.65M shares 10-Q · filed 2025-11-05 | 136.44M shares derived: average of 2 quarters · filed 2025-11-05 | 136.06M shares 10-Q · filed 2025-11-05 | 135.69M shares derived: average of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | 136.22M shares 10-Q · filed 2025-08-06 | 136.23M shares 10-Q · filed 2024-08-01 | 135.76M shares 10-Q · filed 2025-08-06 | 135.37M shares derived: average of 3 quarters · filed 2026-02-23 | 135.10M shares derived: average of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | 135.28M shares 10-Q · filed 2025-05-08 | 134.95M shares derived: average of 2 quarters · filed 2026-02-23 | 134.73M shares derived: average of 3 quarters · filed 2026-02-23 | 134.56M shares derived: average of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | 134.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 134.45M shares derived: average of 2 quarters · filed 2026-02-23 | 134.32M shares derived: average of 3 quarters · filed 2026-02-23 | 134.13M shares 10-K · filed 2026-02-23 | |
| 2023-09-30 | 134.29M shares 10-Q · filed 2024-11-04 | 134.17M shares derived: average of 2 quarters · filed 2024-11-04 | 133.97M shares 10-Q · filed 2024-11-04 | 133.77M shares derived: average of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | 134.06M shares 10-Q · filed 2024-08-01 | 133.81M shares 10-Q · filed 2024-08-01 | 133.59M shares derived: average of 3 quarters · filed 2025-02-27 | 133.38M shares derived: average of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | 133.55M shares 10-Q · filed 2024-05-03 | 133.36M shares derived: average of 2 quarters · filed 2025-02-27 | 133.15M shares derived: average of 3 quarters · filed 2025-02-27 | 132.97M shares derived: average of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | 133.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 132.95M shares derived: average of 2 quarters · filed 2025-02-27 | 132.78M shares derived: average of 3 quarters · filed 2025-02-27 | 132.61M shares 10-K · filed 2025-02-27 | |
| 2022-09-30 | 132.73M shares 10-Q · filed 2023-11-03 | 132.59M shares derived: average of 2 quarters · filed 2023-11-03 | 132.42M shares 10-Q · filed 2023-11-03 | 132.06M shares derived: average of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | 132.45M shares 10-Q · filed 2023-08-04 | 132.33M shares 10-Q · filed 2023-08-04 | 131.84M shares derived: average of 3 quarters · filed 2024-02-26 | 131.54M shares derived: average of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | 132.08M shares 10-Q · filed 2023-05-08 | 131.53M shares derived: average of 2 quarters · filed 2024-02-26 | 131.24M shares derived: average of 3 quarters · filed 2024-02-26 | 130.96M shares derived: average of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | 130.98M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 130.82M shares derived: average of 2 quarters · filed 2024-02-26 | 130.59M shares derived: average of 3 quarters · filed 2024-02-26 | 129.88M shares 10-K · filed 2024-02-26 | |
| 2021-09-30 | 130.67M shares 10-Q · filed 2022-11-03 | 130.39M shares derived: average of 2 quarters · filed 2022-11-03 | 129.52M shares 10-Q · filed 2022-11-03 | 128.97M shares derived: average of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | 130.12M shares 10-Q · filed 2022-08-09 | 128.94M shares 10-Q · filed 2022-08-09 | 128.41M shares derived: average of 3 quarters · filed 2023-02-28 | 127.76M shares derived: average of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | 127.74M shares 10-Q · filed 2022-05-05 | 127.55M shares derived: average of 2 quarters · filed 2023-02-28 | 126.97M shares derived: average of 3 quarters · filed 2023-02-28 | 123.97M shares derived: average of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | 127.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 126.58M shares derived: average of 2 quarters · filed 2023-02-28 | 122.72M shares derived: average of 3 quarters · filed 2023-02-28 | 119.16M shares 10-K · filed 2023-02-28 | |
| 2020-09-30 | 125.81M shares 10-Q · filed 2021-11-04 | 120.40M shares derived: average of 2 quarters · filed 2021-11-04 | 116.43M shares 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | 114.98M shares 10-Q · filed 2021-08-05 | 111.68M shares 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | 30.35M shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |